Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -29.87
- Piotroski Score 4.00
- Grade Neutral
- Symbol (ACER)
- Company Acer Therapeutics Inc.
- Price $0.90
- Changes Percentage (0%)
- Change $0.9
- Day Low $0.90
- Day High $0.90
- Year High $0.90
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/19/2023
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.93
- Trailing P/E Ratio -0.3420207253886
- Forward P/E Ratio -0.3420207253886
- P/E Growth -0.3420207253886
- Net Income $-27,860,371
Income Statement
Quarterly
Annual
Latest News of ACER
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Pacers Signing Of Moses Brown Gives Team Needed Size At Center
The Indiana Pacers are set to sign center Moses Brown to address their need for depth at the position due to injuries. Brown's rebounding and size will be valuable for the team struggling with rebound...
By Forbes | 2 days ago -
Barrett scores season-high 39 as Raptors snap 7-game losing streak, beat Pacers 130-119
The Toronto Raptors ended a seven-game losing streak with a 130-119 victory over the Indiana Pacers. RJ Barrett scored 39 points, Jakob Poeltl had 30 points and 15 rebounds, and the Raptors had all fi...
By AP NEWS | 3 days ago -
Former Black Caps pacer Doug Bracewell served 1 month cocaine ban
Former New Zealand cricketer Doug Bracewell tested positive for cocaine, serving a one-month ban after completing a treatment program. The incident occurred after a domestic match in January, leading ...
By AP NEWS | 4 days ago
